-

Shareholder Alert: Robbins LLP Reminds Investors the Lead Plaintiff Deadline is Tomorrow for Tilray, Inc. (TLRY) Class Action

SAN DIEGO & NANAIMO, British Columbia--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Tilray, Inc. (NASDAQ: TLRY) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between January 15, 2019 and March 2, 2020. Tilray engages in research, cultivation processing, and distribution of medical cannabis.

If you purchased Tilray, Inc. (TLRY) securities between January 15, 2019 and March 2, 2020, you have until May 5, 2020, to ask the court to be appointed lead plaintiff for the class. If you suffered a loss as a result of Tilray' misconduct, click here.

Tilray, Inc. (TLRY) Accused of Misleading Shareholders

According to the complaint, on January 15, 2019, Tilray announced its entry into a marketing and revenue sharing agreement with Authentic Brands Group ("ABG"), touting that "through this agreement, Tilray and ABG [will] join forces at the intersection of science and brand to connect consumers with innovative health and wellness products." Tilray maintained these positive statements throughout the relevant period, assuring investors that the alliance "will complement or augment [its] existing business." Despite auspicious projections for the agreement, on March 2, 2020, Tilray released its financial results for the fourth quarter and full year 2019, reporting a net loss for the year of $321.2 million and disclosing that "the Company recorded non-cash charges of $112.1 million related to impairment of the Authentic Brands Group LLC ('ABG') agreement as well as $68.6 million in inventory reserves." Since this news, Tilray's stock price has precipitously fallen 48% from its closing price of $15.35 per share on March, 2, 2020, currently trading at around $8 per share.

Contact us to learn more:

Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:TLRY

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom